Suzhou Shoutuo Information Technology

Suzhou Shoutuo Information Technology is the Chinese operating entity of Soteria Biotherapeutics, a biotechnology company developing a platform of switchable bispecific T-cell engagers (TCEs) for solid tumors. The company's proprietary T-MATE (T-cell Mobilizing Antigen-specific Therapeutic Engine) platform allows for the activity of the TCE to be controlled by the administration of an FDA-approved small molecule inducer. This approach is designed to provide a wider therapeutic window and reduce the risk of cytokine release syndrome, a common toxicity in T-cell therapy. The company's lead programs, SOT-201 and SOT-301, target GPC3 and Claudin 18.2, respectively, for the treatment of liver and gastric cancers. Based in Suzhou and San Mateo, Soteria is backed by prominent investors including 8VC, Frazier Healthcare Partners, and WuXi AppTec.